<![CDATA[Spartalizumab Triplet Improves OS in BRAF+ Melanoma: COMBI-I Final Analysis]]>

Data ReadoutpositivespartalizumabdabrafenibtrametinibPositive

AI Analysis

Summary

Final COMBI-I trial data demonstrate that spartalizumab combined with dabrafenib/trametinib provides a survival advantage over dabrafenib/trametinib alone in patients with BRAF V600-mutant melanoma.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Spartalizumab plus dabrafenib/trametinib showed survival advantage over dabrafenib/trametinib alone in BRAF V600-mutant melanoma

Importance:7/10

Sentiment:

0.80

melanomaBRAF mutationimmunotherapycombination therapysurvival benefitfinal analysis

Related Companies

$NVS

Read the original article

Published by Cancer Network on August 31, 2026 8:00 PM

Read Original